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Development of a blood-based molecular biomarker test for
identiﬁcation of schizophrenia before disease onset
MK Chan1, M-O Krebs2,3, D Cox1, PC Guest1, RH Yolken4, H Rahmoune1, M Rothermundt5, J Steiner6, FM Leweke7, NJM van Beveren8,
DW Niebuhr9, NS Weber9, DN Cowan9, P Suarez-Pinilla10, B Crespo-Facorro10, C Mam-Lam-Fook2,3, J Bourgin2,3, RJ Wenstrup11,
RR Kaldate11, JD Cooper1 and S Bahn1,8
Recent research efforts have progressively shifted towards preventative psychiatry and prognostic identiﬁcation of individuals
before disease onset. We describe the development of a serum biomarker test for the identiﬁcation of individuals at risk of
developing schizophrenia based on multiplex immunoassay proﬁling analysis of 957 serum samples. First, we conducted a meta-
analysis of ﬁve independent cohorts of 127 ﬁrst-onset drug-naive schizophrenia patients and 204 controls. Using least absolute
shrinkage and selection operator regression, we identiﬁed an optimal panel of 26 biomarkers that best discriminated patients and
controls. Next, we successfully validated this biomarker panel using two independent validation cohorts of 93 patients and 88
controls, which yielded an area under the curve (AUC) of 0.97 (0.95–1.00) for schizophrenia detection. Finally, we tested its
predictive performance for identifying patients before onset of psychosis using two cohorts of 445 pre-onset or at-risk individuals.
The predictive performance achieved by the panel was excellent for identifying USA military personnel (AUC: 0.90 (0.86–0.95)) and
help-seeking prodromal individuals (AUC: 0.82 (0.71–0.93)) who developed schizophrenia up to 2 years after baseline sampling. The
performance increased further using the latter cohort following the incorporation of CAARMS (Comprehensive Assessment of
At-Risk Mental State) positive subscale symptom scores into the model (AUC: 0.90 (0.82–0.98)). The current ﬁndings may represent
the ﬁrst successful step towards a test that could address the clinical need for early intervention in psychiatry. Further
developments of a combined molecular/symptom-based test will aid clinicians in the identiﬁcation of vulnerable patients early in
the disease process, allowing more effective therapeutic intervention before overt disease onset.
Translational Psychiatry (2015) 5, e601; doi:10.1038/tp.2015.91; published online 14 July 2015
INTRODUCTION
Diagnosis of schizophrenia has not changed over the last 100
years since Emil Kraepelin ﬁrst deﬁned the disease and is still
based on evaluation of signs and symptoms in clinical interviews.
If a patient does not acknowledge the occurrence of symptoms of
psychosis, such as hallucinations and delusions, the disease can
remain undiagnosed. In addition, some of the symptoms can also
occur in patients with mood and personality disorders and,
therefore, misdiagnosis is a common occurrence. For example,
Gonzalez-Pinto et al.1 found that approximately one-third of
bipolar patients were diagnosed with schizophrenia or other
psychotic disorders, particularly in youths with short medical
histories. Another complication and reason for the delay in
diagnosis of schizophrenia is the insidious disease onset and the
possibility of multiple or combinatorial causes in the development
or manifestation of the disease.
Over the last two decades, prodromal schizophrenia has
become a major focus of psychiatric research. This condition is
also known as ultra-high-risk syndrome and is normally character-
ized using structured clinical interviews between patients and
psychiatrists for the evaluation of disturbances in perception,
thought processing, language and attention.2 Investigations have
shown that 20–30% of these individuals eventually develop
schizophrenia over a 2–3-year period.3 Early diagnosis of
schizophrenia would be beneﬁcial for the outcome of patients,
especially if this could be achieved before or during the prodromal
stages. This is due to the fact that shorter periods of untreated
psychosis have been linked to better patient outcomes.4 In line
with this, the recent revision of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-5) has led to discussions on the
prodromal syndrome as a potential diagnostic category and this
has now been listed in the DSM-5 appendix as a ‘condition for
further systematic study’.5 However, there is still concern that an
incorrect diagnosis could result in unwarranted treatment and
stigma as ~ 70% of individuals who fulﬁl prodromal criteria do not
develop schizophrenia.2 These concerns highlight the pressing
need to identify robust biomarkers for detection of schizophrenia
before disease onset.
As a ﬁrst step towards addressing this problem, Schwarz et al.6
reported on the identiﬁcation of inﬂammatory, oxidative stress
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and hypothalamic–pituitary–adrenal signalling serum proteins
altered in ﬁrst-onset schizophrenia patients. The next stages in
this research area are to reﬁne and validate such an approach by
developing a serum biomarker panel for improved diagnosis and,
most importantly, to evaluate whether this could be used to
predict the risk of conversion or transition to schizophrenia in at-
risk individuals. Recently, Perkins et al.7 published an algorithm
comprising a panel of 15 analytes identiﬁed in plasma for
prediction of progression of high-risk individuals to psychosis
with an AUC of 0.88. However, due to sample-size limitations, this
algorithm was trained and tested on the same sample set,
examining individuals who did (n= 32) or did not (n= 40) progress
to psychosis and controls (n= 35).
We believe this is the ﬁrst study using a multistage approach to
identify a serum biomarker panel in serum of ﬁrst-onset patients
for the identiﬁcation of individuals at risk of developing
schizophrenia. The ﬁrst stage involved meta-analysis of ﬁve
independent cohorts comprising 331 ﬁrst-onset drug-naive
schizophrenia patients and controls to establish a diagnostic
serum biomarker panel. The next stage involved validation of this
panel using two additional independent cohorts of 181 schizo-
phrenia patients and controls. The third stage was the unbiased
application of this panel to predict development of schizophrenia
in two further independent cohorts of 445 pre-onset or help-
seeking prodromal individuals who were sampled months to years
before disease onset and diagnosis.
MATERIALS AND METHODS
Clinical cohorts
For the ﬁrst phase (discovery phase) of the study, individuals were
recruited consecutively from two clinical centres in Germany (cohort 1,
Central Institute of Mental Health, Mannheim; cohorts 2–4, University of
Magdeburg, Magdeburg) and one in the Netherlands (cohort 5, Erasmus
University MC, Rotterdam). All the patients in cohorts 1–5 were diagnosed
as having the paranoid subtype of schizophrenia (295.30). The samples
were a subset of those used in Schwarz et al.6 and were selected only to
include ﬁrst- or recent-onset antipsychotic-naive schizophrenia patients
and controls with the best matching of demographic characteristics as
indicated in Table 1. For the second phase (validation phase), individuals
were recruited consecutively from clinics in Germany (cohort 6, University
of Muenster, Muenster) and Spain (cohort 7, University of Cantabria,
Santander; for detailed recruitment information, see Pelayo-Teran et al.8;
Table 1). Patients from these cohorts were ﬁrst- or recent-onset and
antipsychotic-naive or unmedicated at the time of sample collection. For
both phases, DSM-IV diagnosis was performed by psychiatrists and
additional analysis included Positive and Negative Syndrome Scale
testing.9 The inter-rater variability was o10% across the sites and
recruitment periods spanned for up to a decade. Information on
antipsychotic medication use was conﬁrmed by direct contact with the
treating family physicians, relatives and spouses along with consultations
regarding detailed current histories of psychotropic medication use before
hospitalization. Controls were recruited simultaneously from the commu-
nity through advertisements or selected from a clinical database of
volunteers (students, staff, relatives of staff and blood donors from local
blood banks) and matched with the respective patient groups for age,
gender and other patient characteristics such as body mass index, smoking
and cannabis, when this information was available (Table 1). For both
patients and controls, the exclusion criteria included: those having ﬁrst-
degree relatives with a medical history of mental disease, diabetes,
cardiovascular disease, immune and autoimmune disorders, infections,
treatment with immunosuppressive/-modulating drugs or antibiotics,
other neuropsychiatric/neurological disorders (multiple sclerosis, epilepsy,
mental retardation), chronic (terminal) diseases affecting the brain (cancer,
hepatic and renal insufﬁciency), alcohol or drug addiction, organic
psychosis/organic affective syndromes, severe trauma, other psychiatric
and non-psychiatric co-morbidity. Exclusions were based on examination
of current medical histories, rating scales, physical examination, blood
tests, magnetic resonance imaging or computed tomography scans, where
possible. Medication was administered after completion of diagnostic
evaluation as appropriate. In addition, informed written consent was given
by all participants and the study protocols, analysis of samples and test
methods were approved by the local Institutional Ethics Review Boards
and were in compliance with the Standards for Reporting of Diagnostic
Accuracy.10
For the third phase of the study, retrospective samples were used, which
were obtained from individuals who were later diagnosed with schizo-
phrenia or bipolar disorder. One set of samples (cohort 8) was selected
from the US Department of Defense Serum Repository (DoDSR), which
contains over 55 million serum specimens remaining from mandatory HIV
test samples of military personnel. Data and sera retrieval for two larger
nested case–control studies were performed by the Armed Forces Health
Surveillance Center (AFHSC) and coordinated by the Military New-Onset
Psychosis Project (MNOPP) investigators at the Walter Reed Army Institute
of Research. The medical and demographic data were provided by the
Defense Medical Surveillance System, AFHSC, US DoD, Silver Spring,
Maryland (the data ranged from 1971 to 2006 and was released in 2007)
and serum samples were retrieved from the DoDSR, AFHSC, US DoD (Silver
Spring, MD, USA; the samples ranged from 1988 to 2006 and were released
in 2007). Sera were then transferred to the Johns Hopkins School of
Medicine (Baltimore, MD, USA) before testing. At the time of sample
collection, the military personnel had not presented with psychiatric
symptoms. Samples were then selected from 185 individuals who later
presented with psychiatric symptoms within 30 days after blood collection
and then received a DSM-IV diagnosis of either schizophrenia (pre-
schizophrenia; 295.10–295.30, 295.60, 295.70, 295.90) or bipolar disorder
(pre-bipolar disorder; 296.00–296.06, 296.40–296.7, 296.80, 296.89; MNOPP;
Table 1).12,13 The diagnostic process leading to medical discharge from
military service and validity of the psychiatric diagnosis has been detailed
elsewhere.13 Control individuals were selected from active duty military
service population with no inpatient or outpatient psychiatric disorder
diagnoses, as conﬁrmed by current military records. All data were
previously collected for other purposes, and analyses were conducted on
de-identiﬁed data. An informed consent waiver was granted by the
Institutional Review Board as only de-identiﬁed data were utilized in
the study.
Cohort 9 consisted of 76 individuals who were referred consecutively to
the Adolescent and Young Adults Assessment Center (SHU, Paris, France)
between 2009 and 2013 and enrolled in the ICAAR collaborative study.
Inclusion criteria included altered global functioning (Social and Occupa-
tional Functioning Assessment Scale (SOFAS) o70) associated with
psychiatric symptoms and/or subjective cognitive complaints, during the
last year. Individuals were excluded who met the DSM-IV-deﬁned criteria
for psychosis, schizophrenia or schizo-affective disorders, pervasive
developmental or bipolar disorders, as were individuals with other
established diagnoses such as obsessive-compulsive disorders. Other
exclusion criteria were current antipsychotic treatment for more than
12 weeks, psychoactive substance dependence or abuse during the
previous year and/or more than 5 years, serious or evolutive somatic and
neurological disorders, head injury and intelligence quotient o70, and
non-French-native speaking status. The Comprehensive Assessment of At-
Risk Mental State (CAARMS) was conducted by speciﬁcally trained
psychiatrists.14 Among the 76 help-seeking prodromal individuals, 50
met the CAARMS threshold criteria for ultra-high risk and 26 did not
(Supplementary Information 1).15 Of the 50 individuals who met the
CAARMS criteria, 14 later developed schizophrenia and 36 did not. Of the
26 individuals who did not meet the CAARMS criteria, 4 developed
schizophrenia and 22 did not. This resulted in a total of 18 help-seeking
prodromal/non-prodromal individuals who later developed schizophrenia
and 58 who did not. Clinical symptoms were assessed using the Brief
Psychiatric Rating Scale 24-item extended version with anchor.16 As carried
out for cohorts 1–7, informed written consent was given by all the
participants, and study protocols, collection and analysis of samples and all
test methods were approved by the local Institutional Ethics Review
Boards.
Serum sample preparation
Standard operating protocols were prepared for serum sample preparation
and used by all the clinical centres, as described previously6 (for details, see
Supplementary Information 2). Samples were randomized and processed
blind to disease status.
Multiplexed immunoassay analyses
The multi-analyte proﬁling immunoassay platform was used to measure
the concentrations of up to 225 analytes in serum samples from the
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respective clinical centres. These analytes are involved in various hormonal,
immune and inﬂammatory, metabolic and neurotrophic pathways. All
assays were conducted in the Clinical Laboratory Improved Amendments
(CLIA)–certiﬁed laboratory at Myriad-RBM (Austin, TX, USA), as described
previously6 (Supplementary Information 3). Instrument performance and
assay reproducibility were assessed using quality control samples which
had a coefﬁcient of variation o15%. The study protocols, analysis of
samples and test methods were carried out in compliance with the
Standards for Reporting of Diagnostic Accuracy initiative.10
Statistical analysis and experimental design
All the statistical analyses were performed in R (http://www.R-project.org/).17
Multiplex immunoassay data from all the nine cohorts were quality
control (QC) assessed and pre-processed to remove analytes with 430%
missing values (QC criteria). Missing values are deﬁned as analytes with
measurement values below or above the detection limits (Supplementary
Table 1). Sample outliers were identiﬁed using principal component
analysis18 through inspection of quantile–quantile plots. Data were
imputed as described previously6 and log10-transformed to stabilize
variance.
The overall strategy was divided into three stages (details of participant
inclusion and assay selection for the ﬁnal biomarker panel are summarized
in Figure 1). The ﬁrst stage involved the development of a biomarker panel,
comprising the best analytes for discriminating ﬁrst-onset drug-naive
patients from controls. This involved meta-analysis (ﬁxed effects model-
ling) of cohorts 1–5 resulting in the exclusion of 53 analytes that failed QC
in one or more of the cohorts and 27 analytes that were signiﬁcantly
affected by disease-association heterogeneity (Supplementary Tables 2
and 3). Batch effects due to runtime of cohorts were eliminated using the
ComBat function in the R package sva.19 No sample outliers were
identiﬁed. The remaining 62 analytes were tested for association with
patient/control status (outcome) using logistic regression (age and sex
were not signiﬁcantly associated). Model assumptions for the associated
analytes were also tested. False discovery rate was controlled according to
Benjamini and Hochberg.20 To reduce the model space and examine the
joint effects of the analytes, which were signiﬁcantly associated with
patient/control status, we applied least absolute shrinkage and selection
operator (LASSO) regression (Supplementary Information 4) with 10-fold
cross-validation to select for the optimal set of discriminatory analytes, as
implemented in the R package glmnet.21,22 The LASSO approach reduces
the coefﬁcients of analytes that have no discriminatory power to zero,
while selecting for variables with nonzero coefﬁcients. These variables
represent analytes that have high joint discriminatory power to separate
patients and controls.23
The next stages involved validating the performance of the panel using
two independent cohorts of patients and controls (cohorts 6 and 7), and
then ﬁnally testing the performance for the prediction of schizophrenia
development using two separate cohorts of pre-onset and at-risk
individuals (cohorts 8 and 9). Predictive performance was evaluated using
the test accuracy, sensitivity, speciﬁcity, predictive values and the area
under the receiver operating characteristic (ROC) curves (AUC) (AUC: 0.9–
1.0 = excellent; 0.8–0.9 = good; 0.7–0.8 = fair; 0.6–0.7 =poor; 0.5–0.6 = fail),
using the R package ROCR.24 Optimal trade-offs between sensitivity and
speciﬁcity were determined by maximizing the Youden's index (J;
calculated by J= sensitivity+speciﬁcity− 1).25 One control sample outlier
was identiﬁed and excluded from cohort 8, through inspection of quantile–
quantile plots. Data QC and pre-processing for cohorts 6, 8 and 9 are
detailed in Supplementary Tables 4 and 5.
RESULTS
The study included a total of 957 participants, comprising 331 in
the discovery metacohort, 181 in the two validation cohorts and
445 in the pre-onset predictive performance testing cohorts
(Table 1, Figure 1). The comparative groups within each cohort
were matched for age and sex, and those in the USA military and
help-seeker/prodromal cohorts were ~ 10 years younger com-
pared with those in the discovery and validation cohorts, as these
individuals were pre-onset at the time of sampling and therefore
likely to be younger than ﬁrst-onset patients.
Stage I. Discovery of a ﬁrst-onset schizophrenia biomarker panel
Meta-analysis of cohorts 1–5, comprising 127 ﬁrst-onset drug-
naive schizophrenia patients and 204 controls led to initial
identiﬁcation of 29 analytes, which were altered signiﬁcantly in
schizophrenia patients compared with controls (see
Supplementary Figure 1 for Forest Plots). This was reﬁned to an
optimal set of 26 analytes using the LASSO regression method
with 10-fold cross-validation (Table 2). Next, testing of the pooled
cohorts 1–5 (discovery metacohort) using the reﬁned 26-analyte
panel resulted in excellent performance with an AUC of 0.96
(sensitivity = 90%, speciﬁcity = 90%, accuracy = 90%). This was
similar to the values obtained with the 29-analyte panel (AUC=
0.96, sensitivity = 91%, speciﬁcity = 88%, accuracy = 89%; Table 3,
Figure 2a). The 26 analytes were involved in six main molecular
functions: lipid transport (apolipoprotein A1 (ApoA1), apolipopro-
tein H (ApoH)), inﬂammation (alpha-2 macroglobulin (A2M), beta-2
microglobulin (B2M), carcinoembryonic antigen (CA), haptoglobin,
interleukin-1 receptor antagonist, interleukin-8 (IL8), interleukin-10
(IL10), interleukin-13 (IL13), macrophage migration inhibitory
factor (MIF), receptor for advanced glycosylation end products,
serum glutamic oxaloacetic transaminase (SGOT), tenascin C (TNC),
von Willebrand factor (vWF)), immune system (immunoglob-
ulin A (IgA)), hormonal signalling (follicle-stimulating hormone
(FSH), leptin, pancreatic polypeptide (PPP), testosterone, thyroid-
stimulating hormone (TSH)), growth factor signalling (AXL receptor
tyrosine kinase, insulin-like growth factor-binding protein 2, stem
cell factor (SCF)) and the clotting cascade (angiotensin-converting
enzyme (ACE), factor VII; Table 2).
Stage II. Validation of the biomarker panel
The next stage involved validating the diagnostic performance
of the 26-analyte panel using samples from two independent
European cohorts comprising 93 ﬁrst-onset schizophrenia patients
and 88 controls (cohorts 6 and 7), with similar characteristics to
the discovery metacohort (Table 1). For the analysis of cohort 6
(Spain), the assays for CA, IL10, IL13 and SGOT were excluded for
failing QC, as described in the Materials and methods. Therefore, a
reduced panel of 22 analytes was tested and this yielded an
excellent AUC of 0.97 (sensitivity = 87%, speciﬁcity = 97%, accu-
racy = 93%; Table 3; Figure 2b). In addition, the full panel was
tested on cohort 7 (Germany), which consisted of schizophrenia
patients only. For this reason, two classiﬁcation algorithms
(logistic regression and linear discriminant analysis) were trained
on the discovery metacohort and tested on cohort 7. This resulted
in correct classiﬁcation (sensitivity) of 89% of the patients
(Table 3).
Stage III. Predictive performance testing of the biomarker panel
For the third phase of the study, the predictive performance of the
panel was tested on the pre-schizophrenia/pre-bipolar disorder
(USA military, cohort 8) and help-seeker/prodromal (cohort 9)
cohorts. All of these individuals were sampled before manifesta-
tion of psychotic symptoms as described in the Materials and
methods section.
For the testing of cohort 8, assays for A2M and IL10 were
excluded for failing QC. This resulted in a ﬁnal panel of 24 analytes.
This cohort comprised 75 pre-schizophrenia and 110 pre-bipolar
disorder individuals and 184 healthy controls. Testing of the 24-
analyte panel gave an excellent AUC of 0.90 for predicting the
development of schizophrenia (sensitivity = 88%, speciﬁcity = 81%,
accuracy = 85%). We then applied the ﬁtted biomarker model on
serum data from 110 pre-bipolar disorder military personnel and
controls. This resulted in an AUC of only 0.53 (sensitivity = 25%,
speciﬁcity = 86%, accuracy = 56%; Table 3; Figure 2c) indicating
that this algorithm fails to predict the development of bipolar
disorder. Further discriminatory performance testing yielded an
Detection of schizophrenia before disease onset
MK Chan et al
4
Translational Psychiatry (2015), 1 – 10
AUC of 0.91 (sensitivity = 88%, speciﬁcity = 83%, accuracy = 85%)
for discriminating pre-schizophrenia from pre-bipolar disorder
military personnel. These results demonstrated that this biomarker
panel has an excellent performance for predicting development of
schizophrenia and high differential diagnostic power for discrimi-
nating schizophrenia from bipolar disorder patients before disease
diagnosis.
For testing of cohort 9, which comprised help-seeking
prodromal individuals (18 who later developed schizophrenia
and 58 who did not), the assays for CA, IL10, IL13 and SGOT were
excluded for failing QC, resulting in a 22-analyte panel (the same
panel tested on cohort 6). Testing the predictive performance of
this panel resulted in an AUC of 0.82 for prediction of transition to
schizophrenia from a prodromal state (sensitivity = 89%, speciﬁ-
city = 66%, accuracy = 71%). We next examined whether this
performance could be improved by incorporation of symptom
scores into the model. This showed that testing the combination
of the 22-analyte panel and CAARMS-positive subscale scores
increased the predictive performance to excellent levels with an
AUC of 0.90 (sensitivity = 89%, speciﬁcity = 79%, accuracy = 82%).
In comparison, testing using the CAARMS-positive subscale scores
alone led to only a fair predictive performance (AUC= 0.72,
sensitivity = 78%, speciﬁcity = 60%, accuracy = 64%; Table 3;
Figure 2d).
I. Discovery of
a SCZ analyte
panel
II. Validation
III. Predictive
performance
testing
Stages
29 analyte panel
Refined to 26 analyte panel
by LASSO regression
Analyte panel
22/26 analyte panel
(4 failed QC)
26 analyte panel
24/26 analyte
panel (2 failed QC)
Five cohort meta-analysis
Cohort 1: 52 controls + 54 SCZ
Cohort 2: 73 controls + 33 SCZ
Cohort 3: 23 controls + 16 SCZ
Cohort 4: 16 controls + 10 SCZ
Cohort 5: 40 controls + 14 SCZ
Cohort 6: 88 controls + 47 SCZ
USA military (n=369)
184 controls
75 pre-SCZ
110 pre-BD
957 subjects included
Discovery metacohort (n=331)
Validation cohorts (n=181)
Test cohorts (n=445)
Cohort 7: 46 SCZ
Prodromal/help-seeker cohort
(n=76)
18 subjects who later developed 
schizophrenia
58 subjects who did not develop 
schizophrenia
22/26 analyte
panel (4 failed QC)
Figure 1. Workﬂow showing participant inclusion and biomarker panel selection/testing over the three phases of analysis. In stage I, meta-
analysis of serum analyte data from cohorts 1–5 was carried out to identify a panel of diagnostic serum biomarkers that discriminates patients
from controls using logistic regression. This led to initial identiﬁcation of 29 signiﬁcant analytes, which was reﬁned to an optimal set of 26
analytes using the LASSO regression with 10-fold cross-validation. In stage II, the optimal panel was validated using independent validation
cohorts. In stage III, predictive performance of the panel was tested in schizophrenia patients before disease onset. Analytes fail QC criteria if
they contain over 30% missing values. BD, bipolar disorder; LASSO, least absolute shrinkage and selection operator; QC, quality control; SCZ,
schizophrenia.
Detection of schizophrenia before disease onset
MK Chan et al
5
Translational Psychiatry (2015), 1 – 10
DISCUSSION
We and others have previously published on the identiﬁcation of
serum protein biomarkers in schizophrenia patients.6,26,27 In the
present study, we extended these ﬁndings by performing a meta-
analysis of ﬁve independent ﬁrst- and recent-onset antipsychotic-
naive schizophrenia patient cohorts and considered the joint
effect of multiple assays in the form of a single biomarker panel
for distinguishing patients from controls with excellent perfor-
mance. We then validated the discriminatory performance of this
panel using two independent cohorts. The strength of this study
was the demonstration that this biomarker panel had a good
predictive performance for identifying individuals who later
converted from either a prodromal or an apparently healthy
psychological state to schizophrenia. Furthermore, incorporation
of symptom scores into the model led to a further increase in
performance to excellent levels for prediction of converters in the
prodromal cohort.
Recent studies, which have investigated other approaches such
as magnetic resonance imaging or psychopathological symptoms
have shown a range of diagnostic accuracies ranging from fair to
excellent (75–92%) for discriminating schizophrenia patients or
pre-onset schizophrenia individuals from controls (for review, see
Zarogianni et al.28). However, most of these studies used relatively
small sample sizes. Gene expression proﬁling studies have also
been carried out by other researchers to identify blood-based
biomarkers for schizophrenia. For instance, Kurian et al.29 applied a
convergent functional genomics approach to identify blood-based
gene expression biomarkers for psychosis. Studies on the use of
blood-based microRNAs as diagnostic biomarkers for schizo-
phrenia30,31 have also been carried out, which achieved a range
of diagnostic accuracies from fair to good (AUC= 0.69–0.85;
Table 2. Table showing analytes altered in patients compared with controls
Molecular function Analyte Abbreviation Single analyte effects (logistic regression) Joint analyte effects
(LASSO selection)
Coefﬁcient s.e. P-value Adjusted
P-value
Coefﬁcient
Lipid transport Apolipoprotein H ApoH 2.67 1.05 0.011 0.032 2.23
Apolipoprotein A1 ApoA1 − 1.48 0.66 0.026 0.062 − 0.31
Inﬂammatory
response
Macrophage migration inhibitory
factor
MIF 2.89 0.48 1.75E− 09 1.56E− 07 2.76
Carcinoembryonic antigen CA 1.77 0.36 1.13E− 06 1.68E− 05 1.69
Tenascin C TNC 2.89 0.62 3.57E− 06 3.97E− 05 1.31
Interleukin-10 IL10 3.55 0.83 1.70E− 05 1.51E− 04 3.63
Interleukin-1 receptor antagonist IL1ra 1.83 0.46 6.27E− 05 4.30E− 04 0.76
Receptor for advanced glycosylation
end products
RAGE − 2.01 0.52 1.10E− 04 7.00E− 04 − 1.36
Interleukin-8 IL8 2.30 0.62 2.12E− 04 1.25E− 03 0.67
Haptoglobin HAPT 1.38 0.37 2.30E− 04 1.25E− 03 1.23
von Willebrand factor VWF 1.69 0.56 0.003 0.010 1.66
Alpha-2 macroglobulin A2M 3.22 1.07 0.003 0.010 4.79
Beta-2 microglobulin B2M − 4.04 1.55 0.009 0.029 − 4.59
Serum glutamic oxaloacetic
transaminase
SGOT 1.90 0.83 0.022 0.055 1.67
Interleukin-13 IL13 1.32 0.67 0.050 0.103 0.19
Immune system Immunoglobulin A IgA − 1.54 0.63 0.015 0.042 − 1.18
Hormonal signalling Pancreatic polypeptide PPP 1.97 0.34 4.12E− 09 1.83E− 07 1.80
Leptin Leptin − 1.55 0.28 5.42E− 08 1.21E− 06 − 0.69
Testosterone (total) TEST 2.08 0.59 4.11E− 04 0.002 0.86
Follicle-stimulating hormone FSH 1.17 0.34 5.19E− 04 0.002 0.33
Thyroid-stimulating hormone TSH − 1.19 0.50 0.017 0.047 0.05
Growth factor
signalling
Insulin-like growth factor-binding
protein 2
IGFBP2 2.96 0.62 1.97E− 06 2.51E− 05 0.33
AXL receptor tyrosine kinase AXL − 2.35 0.82 0.004 0.014 − 3.93
Stem cell factor SCF − 2.20 0.87 0.011 0.032 − 1.72
Clotting cascade Factor VII FVII − 3.92 0.87 6.50E− 06 6.43E− 05 − 2.71
Angiotensin-converting enzyme ACE − 1.39 0.67 0.037 0.082 − 1.14
Hormonal signalling Chromogranin-Aa CGA 0.54 0.24 0.024 0.060 —
Growth factor
signalling
Vascular cell adhesion molecule-1a VCAM-1 − 2.63 1.25 0.036 0.082 —
Inﬂammatory
response
Eotaxina Eotaxin 0.98 0.48 0.041 0.087 —
The analytes are ranked in the order of signiﬁcance within each molecular function group. aNot selected by least absolute shrinkage and selection operator
(LASSO) regression.
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sensitivity = 59–91%; speciﬁcity = 65–81%) for discriminating
schizophrenia patients from controls. However, studies aimed at
identifying blood-based molecular biomarkers predictive of illness
before onset are still rare. Furthermore, the biomarker ﬁeld for
psychiatric disorders is still in its early stages and thus, many
studies still lack validation using independent cohorts. This means
that, over time, only the most robust ﬁndings will survive as more
data become available and more extensive validation studies are
carried out.32
Here, we have identiﬁed and validated a protein-based serum
biomarker panel for the identiﬁcation of ﬁrst-onset schizophrenia
patients using seven independent cohorts of patients and controls
and showed that the same panel could be used with good-to-
excellent diagnostic accuracy for the identiﬁcation of help-seekers
who are at risk of developing a psychiatric illness as well as
psychologically healthy individuals who would later transit to
schizophrenia using two additional international independent
cohorts. Although further validation studies using larger indepen-
dent pre-onset sample sets are still needed, the current ﬁndings
may represent the ﬁrst successful steps in meeting the critical
need for early disease detection in psychiatric medicine. Further
validation of the schizophrenia biomarker candidates identiﬁed
here could also lead to new insights into schizophrenia
pathophysiology. Several limitations need to be taken into
account, which should also form the basis for future studies. We
have previously identiﬁed gender-speciﬁc serum biomarker
patterns in both Asperger's syndrome33 and schizophrenia34
patients. Although no signiﬁcant gender effect was found in our
study, the potential effects of this variable should not be
underestimated. Hence, future studies investigating gender-
speciﬁc markers predictive of transition to schizophrenia are
warranted. Similarly, other confounding variables that could
potentially inﬂuence hormonal regulation and metabolism such
as the use of contraceptives, menstrual cycle phase, body mass
index and smoking could not be accounted for completely in our
analysis as these were either not recorded or only partially
recorded (Table 1). Future studies should attempt to account for
these factors. Another factor which should be taken into
consideration is that all proteins in our study were measured in
serum and we can only speculate about their role in the central
nervous system. However, we have previously reported that
changes in peripheral analyte levels may reﬂect, at least partly,
changes in the brain or vice versa.35 This is further supported by
evidence implicating systemic inﬂuences on brain function
involving the immune and metabolic systems in the precipitation
and course of psychiatric conditions. These studies indicate that
the brain and peripheral systems are intimately connected, which
is also reﬂected in changes in the composition of the blood.36
However, it remains a question of debate whether altered brain
function is the root cause of peripheral changes or whether, more
controversially, peripheral changes precipitate psychiatric symp-
toms. If this was the case, interventions aimed at normalizing
peripheral pathologies associated with mental illness could be
indicated. A number of studies suggest that psychiatric symptoms,
particularly at early stages of the illness, may be alleviated by
targeting affected peripheral pathways such as the immune/
inﬂammatory system. Clinical trials have already shown favourable
therapeutic effects of peripheral administration of anti-
inﬂammatory agents such as COX2 inhibitors (for example,
Celecoxib).37 Finally, we cannot completely rule out the possibility
that cohort 8 (military cohort) could be more similar to the ﬁrst-
onset patient/control cohorts 1–7 given the relatively short
interval (30 days) between blood collection and initial psychiatric
diagnosis. Most of the previous peripheral biomarker studies have
examined patients treated with antipsychotic medication, which
could have a confounding effect on the circulating analytes. It is
difﬁcult to recruit ﬁrst-onset drug-naive patients as even large
psychiatric centres can only recruit around 20–30 of these patients
each year, and few centres follow strict standard operating
procedures for the collection of samples. We overcame this
limitation by including ﬁrst-onset drug-naive patients from
multiple independent clinical centres. Patients were recruited
over a period of up to 10 years in specialist early psychosis centres
or clinics (see Table 1 for recruitment periods). All the patients and
matched controls underwent extensive clinical characterization
and sera were collected and stored according to strict standard
operating procedures and in compliance with the Standards for
Table 3. Assay performance of samples over the three stages of the study
AUC (95% CI) FP TP TN FN PPV (%) NPV (%) Sens (%) Spec (%) FPR (%) Acc (%)
Discovery metacohort (schizophrenia compared with controls)
29-Analyte panel 0.96 (0.938–0.977) 25 116 179 11 82 94 91 88 12 89
Reﬁned 26-analyte panel 0.96 (0.937–0.976) 21 114 183 13 84 93 90 90 10 90
Validation cohorts (schizophrenia compared with controls)
Cohort 6 0.97 (0.952–0.996) 3 41 85 6 93 93 87 97 3 93
Cohort 7 (only SCZ)a, b NA NA 41 NA 5 NA NA 89 NA NA NA
USA military (pre-schizophrenia/pre-bipolar disorder compared with controls)
Pre-SCZ vs CT 0.90 (0.856–0.952) 14 66 61 9 82 87 88 81 19 85
Pre-BDc vs CT 0.53 (0.457–0.611) 15 28 94 82 65 53 25 86 14 56
Pre-SCZ vs pre-BD 0.91 (0.865–0.949) 19 66 91 9 78 91 88 83 17 85
Prodromal/help-seeker cohort (individuals who later developed SCZ compared with those who did not)
22-Analyte panel 0.82 (0.706–0.925) 20 16 38 2 44 95 89 66 34 71
22-Analyte panel + CAARMS positive 0.90 (0.816–0.978) 12 16 46 2 57 96 89 79 21 82
CAARMS positive 0.72 (0.568–0.865) 23 14 35 4 38 90 78 60 40 64
Abbreviations: Acc, accuracy; AUC, area under curve; BD, bipolar disorder; CAARMS, Comprehensive Assessment of At-Risk Mental State; CT, control; FN,
number of false negatives; FP, number of false positives; FPR, false positive rate; NPV, negative predictive value; PPV, positive predictive value; SCZ,
schizophrenia; Sens, sensitivity; Spec, speciﬁcity; TN, number of true negatives; TP, number of true positives. aClassiﬁcation algorithm: logistic regression.
bLinear discriminant analysis (identical results). cThe ﬁtted biomarker model was applied to the serum data from pre-BD individuals and CT to examine its
predictive performance to identify BD before disease onset. Performance of the biomarker testing of all cohorts was evaluated using accuracy, sensitivity,
speciﬁcity, predictive values, receiver operating characteristic (ROC) curves and area under the ROC curve (AUC: 0.9–1.0= excellent; 0.8–0.9= good; 0.7–
0.8= fair; 0.6–0.7=poor; 0.5–0.6= fail). Optimal trade-offs between sensitivity and speciﬁcity were determined by maximizing the Youden's index (J; calculated
by J= sensitivity+speciﬁcity−1).25
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Reporting of Diagnostic Accuracy initiative to maximize reliability
and accuracy of the results.
The majority of the analytes used in the ﬁnal test panel are
involved in inﬂammation and immune system functions, consis-
tent with the ﬁndings from previous studies.6,26,27 Effects on
inﬂammation have been widely reported in schizophrenia and
appear to involve a mixture of pro- and anti-inﬂammatory
responses (for review, see Miller et al.38). Previous studies have
also reported changes in hormones and growth factors such as
chromogranin A, leptin and pancreatic polypeptide.39 Other
analytes on the panel are involved in lipid transport, hormonal
and growth factor signalling and the clotting cascade, in line with
the ﬁndings of other studies.6,40 Changes in all of these pathways
are known to have effects on brain functions such as mood,
emotional responses and cognitive processes.36,41 Again, this
illustrates how changes in peripheral system can affect central
nervous system functions.
Out of our original 29 signiﬁcant analyte panel, 23 were
previously identiﬁed in at least one of the four published
studies,6,7,26,27 which have used a multiplex immunoassay
approach to identify blood-based protein biomarkers for schizo-
phrenia. These molecules include A2M, ApoA1, ApoH, CA, eotaxin,
factor VII, FSH, HPT, IgA, IGFBP2, IL10, IL1ra, IL13, IL8, leptin, MIF,
PPP, SGOT, SCF, testosterone, TSH, VCAM-1 and vWF. However, the
overlap with results reported by each individual study was only
moderate. The main reason for this is that we conducted a more
extensive analysis using very stringent data quality ﬁltration
criteria, including exclusion of analytes that failed QC (430%
missing values) and those affected by signiﬁcant disease-
association heterogeneity. This has resulted in the exclusion of
many of the analytes reported in previous studies (see
Supplementary Table 6 for results overlap with the literature).
For instance, in the Schwarz et al.6 study, 34 molecules were found
to be signiﬁcantly altered in schizophrenia patients relative to
controls. Of these, 19 analytes were excluded in our study as they
either failed QC (eight analytes) or due to disease-association
heterogeneity (11 analytes). So, only 15 signiﬁcant molecules were
measured and analysed in our study. Of these, we found 11 to be
signiﬁcant. Similarly, Schwarz et al.27 subsequently investigated 53
serum molecules involved in immune response and growth factor
signalling and found that based on this proﬁle schizophrenia
patients could be separated into two signiﬁcantly distinct
subgroups. Out of the 53 analytes, 37 were excluded in our study
(24 failed QC and 13 were affected by disease-association
heterogeneity). Only 16 signiﬁcant molecules were measured in
our study, and, of these, we found 10 to be signiﬁcant.
Figure 2. (a) ROC curves showing the diagnostic performance achieved using the 29 original analyte combination and the 26 ﬁnal LASSO-
selected SCZ analyte panel in discriminating SCZ patients (n= 127) from controls (n= 204) (discovery metacohort). (b) ROC curve analysis
showing the diagnostic performance achieved using the SCZ analyte panel for discriminating SCZ patients (n= 47) from controls (n= 88) from
validation cohort 6. (c) ROC curve analysis showing diagnostic performance of the SCZ analyte panel in discriminating pre-SCZ military
individuals (n= 75) from controls who did not develop any subsequent psychiatric illness (n= 75; cohort 8). We then applied the ﬁtted
biomarker model on serum data from pre-BD individuals and controls (110 pre-BD, 109 CT) to examine its predictive performance to identify
BD before disease onset. This biomarker panel was then further tested for its differential diagnostic performance to discriminate pre-SCZ from
pre-BD patients before onset of both diseases. (d) ROC curve analysis showing diagnostic performance of the analyte panel for discrimination
of help-seeking prodromal individuals who later developed schizophrenia (n= 18) from those who did not (n= 58; cohort 9). Note that instead
of the full optimal 26-analyte panel, only 22- and 24-analyte panels were tested in ﬁgures b and d, and c, respectively. This is due to some
analytes failing QC, as described in the methods. AUC, area under curve; BD, bipolar disorder; CAARMS, Comprehensive Assessment of At-Risk
Mental State; CT, control; LASSO, least absolute shrinkage and selection operator; QC, quality control; ROC, receiver operator characteristic;
SCZ, schizophrenia; Sens, sensitivity; Spec, speciﬁcity.
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The results from this and other published ﬁndings may also
differ depending on whether signiﬁcant ﬁndings are reported
based on false discovery rate-adjusted P-values or not. For
example, in the Domenici et al.26 study, 10 markers were identiﬁed
by multivariate analysis of data from schizophrenia patients and
controls. Of these, only six analytes were measured in our study,
two of which were signiﬁcant and four were not. From their
univariate analysis, 55 analytes were found to be signiﬁcantly
altered in patients based on unadjusted P-valueso0.05. Of these
analytes, 30 were excluded in our study (16 failed QC and 14
showed disease-association heterogeneity). As a result, only 25
signiﬁcant molecules were also analysed in our study, and, of
these, we found 14 to be signiﬁcant based on false discovery rate-
adjusted P-values. As Domenici et al. presented unadjusted P-
values, the lack of overlap of the remaining 11 molecules could at
least, in part, be due to the lack of control for false discovery rate.
Perkins et al.7 published the only previous plasma-based protein
biomarker study reporting on a 15-analyte panel for predicting
schizophrenia conversion. Out of these analytes, 11 were excluded
or not measured in our study (three failed QC (IL1 beta, IgE, GH);
six were not measured in the Myriad-RBM assay version used in
this study (MDA-LDL, MMP-7, uromodulin, Apo D, KIT ligand,
chemokine ligand 8); two showed disease-association hetero-
geneity (cortisol, resistin)). Of the four signiﬁcant molecules (TSH,
factor VII, IL7, IL8) which were measured in our study, we found
three to be signiﬁcant (TSH, Factor VII and IL8). Therefore, the lack
of overlap with the ﬁndings of Perkins et al. is primarily due to the
fact that 11 out of 15 analytes (73%) were excluded or not
measured in our study, as explained above. Another difference
could result from the analysis of different blood substrates as the
authors examined plasma and we analysed serum. Furthermore,
Perkins et al. developed their algorithm through training and
testing on the same relatively small cohort of high-risk individuals
that did or did not progress to psychosis and controls. In contrast,
the samples we used to develop our biomarker panel were
obtained from large cohorts of well-characterized ﬁrst-onset drug-
naive schizophrenia patients, who would be expected to show
greater homogeneity in their serum molecular proﬁles with
respect to a ‘schizophrenia signal’ (that is, the 26-analyte panel).
We then demonstrated that this signal was already present at the
pre-onset or prodromal stages of the illness as our biomarker
panel successfully predicted transition to schizophrenia. It is
important to note that we do not imply that analytes that failed
the very stringent criteria applied in the present study are not
relevant for the schizophrenia disease process or signiﬁcant in the
context of another research question. The aim of our study was to
identify the optimal combination of reproducibly measured
analytes capable to diagnose and/or predict schizophrenia disease
status. Future work attempting to reﬁne biomarker panels should
consider testing for those analytes which show the most robust
and reproducible measurements across clinical samples to support
their utility in the clinic. Finally, the multiplex immunoassay
platform used in this study has also been previously applied in
studies, which have attempted to identify serum or plasma
biomarker proﬁles in depression and bipolar disorder patients. Out
of our 26-analyte panel, only three proteins (ApoH, ApoA1 and
B2M) were altered in bipolar disorder patients and four (MIF, ACE,
TNC and ILra) were changed in patients with depression. These
results suggest that biomarker proﬁles for these disorders are
different, although a direct comparison of protein levels in the
same study is required to determine the predictive accuracy of a
given diagnostic panel.
Beyond the prognostic and diagnostic potential of the present
biomarker panel, these ﬁndings may lead to applications for
personalized medicine approaches. For example, patients exhibit-
ing changes in inﬂammation pathways may beneﬁt from anti-
inﬂammatory medication as an adjunctive treatment with
standard antipsychotics.42 Furthermore, this panel shows promise
for future studies aimed at developing a pre-onset differential
diagnostic test. We demonstrated that our biomarker panel had a
high discriminatory power to differentiate individuals who would
later be diagnosed with schizophrenia from those who would later
receive a diagnosis of bipolar disorder.
The debates surrounding the prodromal syndrome arise from
the lack of diagnostic tools to accurately predict or identify those
individuals who will go on to develop schizophrenia (an estimated
20–30% of ultra-high-risk individuals, over a 2–3-year period). This
raises ethical issues regarding stigmatization and the potential for
inappropriate treatment. All clinical tests have a chance of false
diagnosis, which should be considered in the context of a clinical
application. In testing the prodromal cohort, we found that the
combination of the molecular and symptom-based tests resulted
in a higher performance (AUC= 0.90) than could be achieved with
either test alone. We do not propose that this test should be used
to screen the general population, but the data suggest that
application of this test in conjunction with currently used
structured interviews may aid in earlier and more accurate
diagnosis of schizophrenia and thereby facilitate early intervention
and improved clinical outcomes.
Market analysis has shown that psychiatrists would value a
blood test that could help in the prediction of conversion in
prodromal individuals.43 The biomarker panel presented here
represents a validated set of biomarkers from which a deﬁnitive
signature for diagnosis and prediction of schizophrenia in the
clinical setting could be developed. Ultimately, further develop-
ments of the biomarker panel could form the basis of a low-cost
blood test, which can complement DSM-5 or ICD-10-based
diagnostic approaches. We suggest that the use of such a test
in conjunction with a psychiatric assessment will help to position
schizophrenia among other biological disorders, such as diabetes
and heart disease, ameliorating the stigma and providing hope for
better diagnostic and treatment approaches.
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